학술논문
Hepatocellular Carcinoma Risk Assessment for Patients With Advanced Fibrosis After Eradication of Hepatitis C Virus
Document Type
article
Author
Nobuharu Tamaki; Masayuki Kurosaki; Yutaka Yasui; Nami Mori; Keiji Tsuji; Chitomi Hasebe; Kouji Joko; Takehiro Akahane; Koichiro Furuta; Haruhiko Kobashi; Hiroyuki Kimura; Hitoshi Yagisawa; Hiroyuki Marusawa; Masahiko Kondo; Yuji Kojima; Hideo Yoshida; Yasushi Uchida; Toshifumi Tada; Shinichiro Nakamura; Satoshi Yasuda; Hidenori Toyoda; Rohit Loomba; Namiki Izumi
Source
Hepatology Communications, Vol 6, Iss 3, Pp 461-472 (2022)
Subject
Language
English
ISSN
2471-254X
Abstract
The identification of patients with advanced fibrosis who do not need any further hepatocellular carcinoma (HCC) surveillance after the eradication of hepatitis C is pivotal. In this study, we developed a simple serum‐based risk model that could identify patients with low‐risk HCC. This was a nationwide multicenter study involving 16 Hospitals in Japan. Patients with advanced fibrosis (1,325 in a derivation cohort and 508 in a validation cohort) who achieved sustained virological responses at 24 weeks after treatment (SVR24) were enrolled. The HCC risk model at any point after SVR24 and its change were evaluated, and subsequent HCC development was analyzed. Based on the multivariable analysis, patients fulfilling all of the factors (GAF4 criteria: gamma‐glutamyl transferase